Bartosz Kopeć, Mateusz Sikora, Sylwia Słuczanowska-Głąbowska, Andrzej Pawlik
The role of PARP inhibitors in treatment of selected cancers associated with mutations in BRCA1 and BRCA2 genes
Common cancers related to mutations in BRCA1/BRCA2 genes are breast cancer, ovarian cancer, panceatic cancer. BRCA1 and BRCA2 are tumor supresor genes which function is DNA repair. PARP inhibitors, similarly to damaged BRCA1/BRCA2 proteins handicap process of DNA repairment. Therapy with PARP inhibitors, with presence of inherited defects in DNA repair in cancer cells, cause accumulation of DNA damages what leads to synthetic lethality, but with limited influence on healthy cells. In 2014 olaparib was registered, as first of PARP inhibitors, in therapy of ovarian cancer related to BRCA1/BRCA2 mutation. In 2018 indications to olaparib apply have been expanded with metastatic breast cancer associated with BRCA1/BRCA2 mutation, which enabled to almost double the time without significant growth of tumor, when compared to classic chemotherapy.
Keywords: breast neoplasms, ovarian neoplasms, olaparib.
© Farm Pol, 2019, 75(3): 129–133